Precigen, Inc. (PGEN) vs Arcus Biosciences, Inc. (RCUS)
Precigen, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcus Biosciences, Inc. is the larger, with a market value of $3.2B against $2.8B — 1.1× the size. Precigen, Inc. grew revenue faster over the last twelve months: 1,875.1% against −55.3%. Precigen, Inc. has the higher net margin (−392.8% vs −393.2%) and the lower return on invested capital (−24.9% vs 0.00%). Across the 18 metrics below, Arcus Biosciences, Inc. leads on 10 and Precigen, Inc. on 8.
Valuation
Profitability
| Metric | PGEN | RCUS | Biotechnology median |
|---|---|---|---|
| Gross margin | 90.67% | 100.00% | 65.16% |
| Operating margin | (46.08%) | (415.38%) | 0.00% |
| Net margin | (392.81%) | (393.16%) | 0.00% |
| Free cash flow margin | (134.42%) | (405.13%) | 0.00% |
| Return on equity | (9,907.46%) | (90.82%) | (57.72%) |
| Return on assets | (247.40%) | (46.02%) | (49.22%) |
| Return on invested capital | (24.87%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack